The pathway regulating MDM2 protein degradation can be altered in human leukemic cells

Cancer Research

Volumn 59, Issue 9, 1999, Pages 2064-2067

  Pan, Yi ^a,b   Haines, Dale S ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2;

ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; GENE ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE;

BURKITT LYMPHOMA; CELL DIVISION; CYCLOHEXIMIDE; CYSTEINE ENDOPEPTIDASES; GENES, P53; HALF-LIFE; HUMANS; JURKAT CELLS; LEUKEMIA, T-CELL, ACUTE; LEUKOCYTES, MONONUCLEAR; LEUPEPTINS; MULTIENZYME COMPLEXES; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SYNTHESIS INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033135062     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Fakharzadeh, S. S., Trusko, S. P., and George, D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 19: 1565-1569, 1991.
2. Finlay, C. A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol., 13: 301-306, 1993.
3. Leach, F. S., Tokino, T., Meltzer, P., Burell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W., and Vogelstein, B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53: 2231-2234, 1993.
4. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
5. Oliner, J. D., Pientenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (Lond.), 362: 857-860, 1993.
6. Kubbulat, M. H. G., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by MDM2. Nature (Lond.), 387: 299-303, 1997.
7. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. MDM2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
8. Barak, Y., Juven, T., Haffner, R., and Oren, M. MDM2 expression is induced by wild type p53 activity. EMBO J., 12: 461-468, 1993.
9. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132, 1993.
10. de Oca Luna, R. M., Wagner, D. S., and Lozano, G. Rescue of early embryonic lethality in MDM2-deficient mice by deletion of p53. Nature (Lond.), 378: 203-206, 1995.
11. Jones, S. N., Roe, A. E., Donehower, L. A., and Bradley, A. Rescue of embryonic lethality in MDM2-dificient mice by absence of p53. Nature (Lond.), 378: 206-208, 1995.
12. Bull, E. K., Chakrabarty, S., Brodsky, I., and Haines, D. S. MDM2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells. Oncogene, 16: 2249-2257, 1998.
13. Marks, D. I., Vonderheid, E. C., Kurz, B. W., Bigler, R. D., Sinha, K., Morgan, D. A., Sukman, A., Nowell, P. C., and Haines, D. S. Analysis of p53 and MDM2 expression in 18 patients with Sezary syndrome. Br. J. Haematol., 92: 890-899, 1996.
14. Barak, Y., Gottlieb, E., Juven-Gershon, T., and Oren, M. Regulation of MDM2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev., 8: 1739-1749, 1994.
15. Landers, J. E., Cassel, S. L., and George, D. L. Translational enhancement of MDM2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res., 57: 3562-3568, 1997.
16. Cahng, Y. C., Lee, Y. S., Tejima, T., Tananka, K., Omura, S., Heintz, N. H., and Mitsui, J. MDM2 and bax, downstream mediators of the p53 response, are degraded by the uniquitin-proteasome pathway. Cell Growth Differ, 9: 79-84, 1998.
17. Mercer, W. E., and Baserga, R. Expression of the p53 protein during the cell cycle of human peripheral blood lymphocytes. Exp. Cell Res., 160: 31-46, 1985.
18. r 53,000 tumor antigen messenger RNA in normal and neoplastic cells. Cancer Res., 46: 5738-5742, 1986.
19. Sigalas, I., Calver, A. H., Anderson, J. J., Neal, D. E., and Lunec, J. Alternatively spliced MDM2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med., 2: 912-917, 1996.
20. Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., and Finlay, C. A. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev., 11: 714-725, 1997.
21. Sun, P., Dong P., Dai, K., Hannon, G. J., and Beach, D. p53-independent role of MDM2 in TGF-β1 resistance. Science (Washington DC), 282: 2270-2272, 1998.
22. Jones, S. N., Hancock, A. R., Vogel, H., Donehower, L. A., and Bradley, A. Overexpression of MDM2 in mice reveals a p53-independent role for MDM2 in tumorigenesis. Proc. Natl. Acad. Sci. USA, 95: 15608-15612, 1998.
23. Cordon-Cardo, C., Latres, C., Drodnjak, M., Olivia, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. Molecular abnormalities of MDM2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994.
24. Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H., and Peters, G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J., 17: 5001-5014, 1998.
25. INK4A/MTS gene. Oncogene. 15: 2475-2481, 1997.